Replimune Group (Nasdaq:REPL) - 주가, 뉴스 및 분석

REPL 주식 개요

리플리뮨 그룹은 임상 단계의 생명공학 회사로 암 치료를 위한 종양 용해성 면역 요법 개발에 주력하고 있습니다. 자세한 내용

REPL 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 45.6% 에서 거래

수익은 연간 57.42% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 3개월간 상당한 내부자 매도

최근 3개월간 주가 변동성

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

+ 1 더 많은 위험

Replimune Group, Inc. 경쟁사

Autolus Therapeutics

NasdaqGS:AUTL

US$823.6m

Anavex Life Sciences

NasdaqGS:AVXL

US$766.1m

Relay Therapeutics

NasdaqGM:RLAY

US$796.7m

Prothena

NasdaqGS:PRTA

US$838.3m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Replimune Group
과거 주가
현재 주가	US$14.05
52주 최고치	US$17.00
52주 최저치	US$4.92
베타	1.19
11개월 변경	16.60%
3개월 변경 사항	27.03%
1년 변경 사항	24.12%
33년 변화	-49.84%
5년 변화	3.69%
IPO 이후 변화	-7.32%

최근 뉴스 및 업데이트

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Nov 23

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Estimating The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Sep 02

주주 수익률

	REPL	US Biotechs	US 마켓
7D	25.1%	4.0%	2.0%
1Y	24.1%	18.0%	32.4%

수익률 대 산업: REPL 지난 1년 동안 18 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: REPL 지난 1년 동안 32.4 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is REPL's price volatile compared to industry and market?
REPL volatility
REPL Average Weekly Movement	13.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

안정적인 주가: REPL 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: REPL 의 주간 변동성( 13% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2015	331	Sush Patel	www.replimune.com

리플리뮨 그룹은 임상 단계의 생명공학 회사로 암 치료를 위한 종양 용해성 면역 요법 개발에 주력하고 있습니다. 이 회사의 독점적인 종양 지향적 종양 용해 면역 치료 제품 후보들은 암에 대한 면역 체계를 활성화하도록 설계 및 고안되었습니다. 주요 제품 후보로는 다양한 고형 종양에 대한 임상 1상/2상 시험을 진행 중인 GALV-GP R(-)과 인간 GM-CSF를 발현하는 HSV-1의 선택적 복제 버전인 RP1이 있습니다.

Replimune Group, Inc. 기본 사항 요약

Replimune Group 의 수익과 매출은 시가총액과 어떻게 비교하나요?
REPL 기본 통계
시가총액	US$983.84m
수익(TTM)	-US$213.02m
수익(TTM)	n/a

0.0x

P/S 비율

-4.5x

P/E 비율

REPL 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
REPL 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$213.02m
수익	-US$213.02m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-3.11
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	11.9%

REPL 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

REPL 주식 개요

보상

위험 분석

Replimune Group, Inc. 경쟁사

NasdaqGS:AUTL

US$823.6m

NasdaqGS:AVXL

US$766.1m

NasdaqGM:RLAY

US$796.7m

NasdaqGS:PRTA

US$838.3m

가격 내역 및 성능

최근 뉴스 및 업데이트

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Recent updates

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?

A Look At The Fair Value Of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group, Inc. Announces Executive Appointments

Chief Business Officer exercised options and sold US$360k worth of stock

Price target increased to US$48.89

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

Replimune Group, Inc. announced that it has received $200 million in funding from Hercules Capital, Inc. and other investors

Replimune secures $200M term loan

Replimune: Recent Developments Strengthen Bull Thesis